Nivolumab Demonstrates Efficacy in Preliminary Data for Gastric Cancer

July 16, 2020
Yu Sunakawa, MD, PhD

Yu Sunakawa, MD, PhD, discusses the data observed in the DELIVER trial, which was presented as an updated analysis of nivolumab in patients with advanced gastric cancer at the European Society of Oncology World Congress on Gastrointestinal Cancer 2020.

Yu Sunakawa, MD, PhD, an oncologist in the Department of Clinical Oncology at St. Marianna University School of Medicine, discusses the data observed in the DELIVER trial (UMIN000030850), which was presented as an updated analysis of nivolumab (Opdivo) in patients with advanced gastric cancer at the European Society of Oncology World Congress on Gastrointestinal Cancer 2020.

Sunakawa and the other investigators presented the clinical outcomes of therapy with nivolumab, anti-PD-1-based immunotherapy, in real-world setting at this year’s meeting. The findings including preliminary data for tumor response, tumor growth rate, hyper-progressive disease rate, survival time and safety.

The efficacy results showed that the response rate was 6.7%, and the disease control rate (DCR) was 39%, according to DCR of approximately 40% for patients with a performance status of 0 or 1. For those with a performance status of 2, there was a rate of 24%. The DCR was lower in patients with ascites at 28.6% compared with patients without this condition at 47.0%.

Sunakawa believes it’s interesting that they observed hyper-progressive disease in approximately 20% of patients who received nivolumab treatment in this study.

<< View more resources and information regarding gastric cancer